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Abstract
The novel endosome protein, p18, and the early endosome GTPase, Rab4, play a significant role in protecting the pulmonary vasculature
against permeability associated with acute respiratory distress syndrome. Recently, endothelial-derived extracellular vesicles have been
identified to play a key role in the endothelial permeability associated with acute respiratory distress syndrome. Therefore, we
investigated the effect of these microparticles, released from endothelial cells overexpressing p18 and Rab4, on pulmonary endothelial
barrier function. Endothelial-derived extracellular vesicles isolated from lung microvascular endothelial cells which overexpressed cDNA
for wild-type p18 protected a naı¨ve monolayer against lipopolysaccharide-induced permeability. In contrast, endothelial-derived extra-
cellular vesicles from cells overexpressing the non-endosomal binding p18 mutant (p18N39) exerted no protective effect on the endo-
thelial monolayer. Cells overexpressing either dominant active or inactive Rab4 released endothelial-derived extracellular vesicles which
had no effect on lipopolysaccharide-induced permeability. miRNA analysis and permeability studies of endothelial-derived extracellular
vesicle isolated from wild-type p18-overexpressing cells demonstrates that let-7i-5p, miR-96-5p, and miR-137-3p are endothelial-derived
extracellular vesicle cargo which exert protective effects on the pulmonary endothelium. Finally, we observed down-regulation of p18
protein expression in both the lung and endothelium in an in vivo and in vitro model of acute respiratory distress syndrome. These
results demonstrate that endothelial-derived extracellular vesicle released from cells overexpressing p18, but not Rab4, contain miRNA
cargo which likely promote a barrier-protective effect on the pulmonary endothelium in settings of acute respiratory distress syndrome.
Findings indicate the importance of p18 in the pulmonary vasculature and demonstrate that targeting this protein may provide a novel
therapeutic strategy to reduce endothelial permeability associated with acute respiratory distress syndrome.
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Introduction
Over 10% of patients in intensive care units worldwide
suffer from acute respiratory distress syndrome (ARDS),
associated with a mortality rate of nearly 40%.1,2 The
main predisposing factors which lead to ARDS are pneu-
monia, major surgery, trauma, or sepsis.3 Patients with
ARDS suffer from acute hypoxemic respiratory failure asso-
ciated with low oxygen partial pressure (<300mmHg) des-
pite high positive end-expiratory pressure (>5 cmH2O).
3
Due to the complexity and diversity of patient cases,
mechanical ventilation is one of the key therapeutic
approaches for ARDS to improve hypoxemia; however,
this treatment has been linked to worsening of the respira-
tory failure for some patients.4 One of the hallmarks of
ARDS is an increase in lung endothelial permeability, asso-
ciated with the development of pulmonary edema in these
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patients.3 It is therefore vital to understand the mechanisms
which regulate endothelial permeability, with the aim of
reducing respiratory failure in patients with ARDS.
Endothelial-derived extracellular vesicles (EDEVs) have
been identified to play a role in ARDS as a mechanism of
communicating pathological signals and as potential bio-
markers for the disease.5,6 These vesicles range in size
from 50 nm up to 1 mm and are shed from activated endo-
thelial cells in response to stimuli such as cytokines, mech-
anical stress, or the endotoxin lipopolysaccharide (LPS).7,8
The cargo of EDEVs, surrounded by an intact lipid bilayer,
includes a sampling of the endothelial parent cell contents,
such as surface proteins, lipids, miRNAs, or transcription
factors or organelles.9,10 In various models of ARDS, an
increase in EDEVs in the circulation has been demonstrated
with downstream effects on the vasculature through reduced
nitric oxide production, coagulation, elevated release of
inflammatory cytokines, and disruption of the endothelial
barrier.6,10,11 Studies into the composition of these patho-
genic EDEVs demonstrate a role for structural and surface
proteins, such as vinculin and moesin, which have been
linked to increased permeability in the pulmonary endothe-
lium.8,12,13 In recent years, miRNA have been identified as
extracellular vesicle cargo which are altered dramatically in
disease states such as hyperoxia and inflammation.14,15
These small non-coding RNA molecules target the majority
of protein-coding transcripts and, as such, are involved in
nearly all pathological processes.16 Understanding the
miRNA composition and release of EDEVs therefore pre-
sents a potential therapeutic approach to reduce vascular
leak, and therefore pulmonary edema, in settings of ARDS.
We have previously demonstrated a role for two endoso-
mal proteins, Rab4 and p18, in reducing pulmonary endo-
thelial permeability in both in vitro and in vivo models of
ARDS.17,18 Both Rab4 and p18 bind to the early endosome
to facilitate trafficking of vascular endothelial (VE)-cadherin
to the endothelial cell surface, to promote formation of the
adherens junction, and tighten the endothelial barrier. Rab4
is a GTPase which binds to the early endosome to regulate
rapid shuttling of cargo to the cell surface for exocytosis.19
In contrast, p18 has been localized to the early and late
endosome where it plays a role in trafficking and mTOR
signaling, respectively.17,20,21 Given the protective effect of
these two endosomal proteins on the pulmonary vascula-
ture, and the emerging role of EDEVs in regulating the
endothelial barrier, we sought to establish whether release
of these microparticles, from cells overexpressing Rab4 and
p18, are linked to barrier function in the pulmonary
endothelium.
Materials and methods
Cell lines and reagents
All materials were obtained from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. Rat lung microvascular
endothelial cells (LMVEC; VEC Technologies, Rensselaer,
NY) were maintained in MCDB-131 (VEC Technologies)
and used between passages 3 and 11. LPS (endotoxin)
from Escherichia coli serotype 0111:B4 was obtained from
Enzo Life Sciences (Plymouth Meeting, PA). Pseudomonas
aeruginosa strain PA103 was a kind gift from Dr. Troy
Stevens (University of South Alabama, Mobile, AL). The
vector encoding wild-type p18 (GFP-p18wt) and mutant p18,
lacking endosome binding region (p18N39) were a kind gift
from Shigeyuki Nada20 (Department of Oncogene Research,
Osaka University). p18 siRNA (SR513910) and the non-
specific, scrambled control siRNA were purchased from
Origene (Herford, Germany). The vectors encoding domin-
ant active (Rab4Q67L) and dominant negative (Rab4S22N)
Rab4 were a kind gift from Mary McCaffrey (Cell and
Molecular Biology, University College Cork).22 Green fluor-
escent protein vector (pGFP-C1) was obtained from
Clontech (Mountain View, CA). Polyjet was obtained
from SignaGen Laboratories (Rockville, MD), and antibo-
dies directed against p18 were obtained from Abcam
(Cambridge, MA). miRNA mimics and DharmaFECTTM
reagent 4 were obtained from Dharmacon (Cambridge,
UK): rno-miR-30a-5p (C-320328-03), rno-let-7i-5p (C-
320293-05), rno-miR-103-3p (C-320345-03), rno-miR-96-5p
(C-320339-03), rno-miR-196a-5p (C-320241-03), rno-miR-
324-5p (C-320341-03), and rno-miR-137-3p (C-320368).
In vivo model of ARDS
A single dose of live bacteria (P. aeruginosa PA103), or
vehicle of phosphate buffered saline (PBS), was adminis-
tered to a total of 10 male C57BL6 mice via intratracheal
injection (107 CFU). At four hours following PA103 deliv-
ery, mice were delivered a sub-lethal dose of pentobarbitone
and anesthetic effects were tested by toe pinch. Lungs were
removed from mice, prior to exsanguination under anes-
thetic, snap frozen, and stored at –80C until use. All
animal experimental protocols were approved by the
Institutional Animal Care and Use Committees of the
Providence Veterans Affairs Medical Center and our
University, and comply with the Health Research
Extension Act and U.S. Public Health Service policy.
Western blotting
Lungs were homogenized for two minutes in homogeniza-
tion buffer (20mM 4-(2-hydroxyethyl)piperazine-1-ethane-
sulfonic acid (HEPES) pH 7.9, 1.5mM NaCl, 0.25M
sucrose, 0.2mM EDTA, 200mM phenylmethylsulfonyl-
fluoride (PMSF), 0.5mM 1,4-dithiothreitol (DTT), and
1.5mM MgCl2). Protein concentration was then analyzed
and 100 mg protein was prepared in Laemmli buffer for
Western blot analysis. Western blotting was performed on
lung homogenates or cell lysates, as previously described.17
Previously verified antibodies directed against p18 (Abcam,
ab121157) were used, with actin (Santa Cruz, C-11) as a
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load control.17 Densitometry of Western blotting data was
quantified using ImageJ and normalized to controls.
Extracellular vesicle isolation
Rat LMVECs were transiently transfected, using Polyjet
reagent, with plasmid cDNA encoding GFP-tagged con-
structs: wild-type (p18wt) and non-endosomal binding
(p18N39) p18, dominant active (Rab4Q67L), and non-endoso-
mal binding (Rab4S22N) Rab4, or GFP vector control.
Alternatively LMVECs were transiently transfected with
p18 or scrambled control siRNA (300 nM) using
DharmaFect4. Overexpression of constructs was assessed
by GFP fluorescence quantified using the Victor fluorometer
(Perkin Elmer). At 42 h post-transfection, cells were exposed
to LPS (1 mg/ml) for a further six hours. Media from cells
was then removed and centrifuged at 300 g, 4C for 10min
twice, with pellet discarded each time. Supernatant was then
centrifuged at 100,000 g, 4C for one hour. The pellet,
comprising of EDEVs, was resuspended in sterile
Dulbecco’s PBS (DPBS) for permeability assays and quan-
tification using qNano Gold (Izon Science) at 0.5V, 45mm
stretch, 15 mbar pressure, using the NP200 pore and nor-
malized to media as a control, RNAlater for miRNA ana-
lysis, or lysed for protein concentration analysis.23,24
Permeability measurements
Changes in monolayer resistance were measured using the
electrical cell impedance sensor (ECIS) technique and fluor-
escein isothiocyanate (FITC) dextran permeability
technique25 as previously described.17 Naı¨ve, un-transfected
LMVECs were plated on collagen-coated ECIS arrays or
Transwell inserts and cultured for 24 h, prior to exposure
to freshly-prepared EDEVs, in the presence and absence
of LPS (1 mg/ml). Permeability was measured for 10 h
(ECIS) or at 10 h (FITC dextran monolayer flux). The
latter studies were performed using 10 mg/ml FITC-conju-
gated 4 kD dextran which was added to the upper chamber
for 30min prior to the collection period. Collected media
(100ml) from the lower chamber was measured for FITC
concentration using fluorometry (495/520 nm ex/em).
Permeability (%) was calculated by fluorescence accumu-
lated in the lower chamber divided by fluorescence in the
upper chamber, multiplied by 100 and data was normalized
to GFP vehicle.
miRNA analysis
miRNA cargo in isolated EDEVs was assessed using the
miScript miRNA PCR array Rat miFinder kit (Qiagen
MIRN-001Z). Manufacturer’s instructions were followed
for the isolation of RNA from isolated EDEVs and the
array was run as indicated in guidelines. Data were collected
using the Roche Light cycler 480. The second derivative
maximum setting was used to obtain CT values from the
Light Cycler. An automated baseline was established using
the Light Cycler, and the threshold value for all profiler
arrays was established within the lower third of the linear
phase of amplification plots. Raw CT data were then
exported to Excel for further analysis. Data were normalized
for miRNA expression to stably-expressed housekeeping
genes (SNORD68, SNORD95, and SNORD96A).
miRNA mimic transfection
miRNA mimics, scrambled non-specific (ns) miRNA, and
cel-miR67-Dy547 control (10 nM) were transiently trans-
fected into LMVEC using the DharmaFECTTM 4 reagent
protocol, as per manufacturer’s guidelines, for 48 h.
Transfection efficiency was established using cel-miR67-
Dy547 control assessed with fluorometry (557/570 nm ex/
em).26 Transfected LMVECs were plated on transwell
inserts and monolayer permeability was studied as described
in ‘‘permeability measurements’’. Cell viability of LMVEC
transfected with miRNA mimics was assessed using CCK8
assay, as per the manufacturer’s guidelines, with absorbance
read at 450 nm.25
Statistical analysis
The experimental number is presented in the legend for each
experiment. For two groups, the variance in data sets was
analyzed using the Mann–Whitney test followed by the
T-test. In the case of miRNA analysis, the Benjamini–
Hochberg correction was used with the R ‘‘stats’’ package.
For three or more groups, variance was assessed by using
Bartlett’s test with data sets not reaching significance stu-
died by Kruskal–Wallis test followed by Dunn’s test.
Significance was reached when p< 0.05. Values are pre-
sented as mean standard error mean (S.E.M.).
Results
Endothelial cells overexpressing endosomal p18 release
EDEVs which are protective against LPS-induced barrier
permeability
We have previously demonstrated a role for the endosomal
protein p18 in tightening the pulmonary endothelial bar-
rier.17 Given the role of EDEVs in mediating barrier integ-
rity,6 we sought to investigate whether p18 overexpression
had an impact on the ability of extracellular vesicles to regu-
late pulmonary endothelial barrier function. EDEVs were
isolated from LMVECs overexpressing p18wt, non-endo-
some binding p18 mutant (p18N39), or GFP control.
Isolated EDEVs were then used to treat a naı¨ve monolayer,
using LPS as a model of endothelial barrier disruption, and
permeability was assessed via ECIS (Fig. 1a–c and e–f) and
FITC-dextran monolayer flux assay (Fig. 1d and h). In the
absence of LPS, endothelial permeability of the naı¨ve mono-
layer was unaffected following exposure to EDEVs isolated
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from cells overexpressing any of the p18 or GFP constructs
(Fig. 1a–d(i)). In the presence of LPS and EDEVs derived
from GFP-overexpressing cells, monolayer resistance was
significantly disrupted with an increase in permeability
(Fig. 1). Interestingly, EDEVs derived from p18wt-overex-
pressing endothelial cells were protective against LPS-
induced permeability (Fig. 1a, c, and d(i)); however,
EDEVs isolated from p18N39-overexpressing cells exerted
no protective effect (Fig. 1b–d(i)). In addition, EDEVs
were isolated from LMVECs where p18 expression was
knocked down with the use of specific siRNA. siRNA
knockdown was confirmed by Western blotting of
LMVEC lysates, with p18 protein expression significantly
reduced compared to the non-specific control siRNA (ns
siRNA: 87.3 10.1 a.u. versus p18 siRNA: 39.8 5.6 a.u).
EDEVs isolated from p18 knockdown LMVEC had no
impact on endothelial permeability following either vehicle
or LPS treatment (Fig. 1d(ii)). These data indicate that p18
overexpression results in the production of protective
EDEVs and this mechanism is reliant on p18 protein expres-
sion and on the ability of p18 to bind to the endosome.
As we have previously demonstrated that overexpression
of p18wt cDNA in LMVEC protects against LPS-induced
permeability,17 we next assessed whether EDEVs exert a
barrier-protective effect through releasing vesicles with ele-
vated p18 protein within. Whilst increased expression of
GFP was observed in transfected endothelial cells for
p18wt, p18N39, and GFP control vector, the EDEVs derived
Fig. 1. LPS-induced permeability is attenuated by extracellular vesicles isolated from endothelial cells overexpressing wild-type p18, but not
dominant positive Rab4 (Rab4S22N) or non-endosomal p18 and Rab4 mutants (p18N39 and Rab4Q67L). Equivalent numbers of LMVECs were
transiently transfected with p18wt (panel a, c, d(i)) p18N39 (panel b, c, d(i)), Rab4Q67L (panel e, g, h), Rab4S22N (panel f, g, h), and GFP cDNA as a
vector control. Alternatively knockdown of p18 expression was performed in LMVEC with non-specific siRNA used as a control (panel d(ii)).
Following 48 h, extracellular vesicles were isolated from the endothelial monolayer and assayed for concentration and protein concentration.
Naive, untransfected LMVEC monolayers were (all panels) treated with equal concentration of isolated EDEVs (20 mg) for 30min prior to the
addition of LPS (1 mg/ml) or vehicle. Representative traces (panels a, b, e, f), drop in monolayer resistance (panels c and g), and % permeability from
the FITC monolayer flux assay (panels d and h) are shown. Panels a, b, e, f: arrows indicate addition of EDEV and LPS: * EDEV from LMVEC
overexpressing GFP, monolayer treated with vehicle, « EDEV from LMVEC overexpressing GFP, monolayer treated with LPS;  EDEV from
LMVEC overexpressing protein of interest, monolayer treated with vehicle; # EDEV from LMVEC overexpressing protein of interest, monolayer
treated with LPS. Data are presented as mean SEM. n¼ 5–6. *p< 0.05 vs vehicle.
GFP: green fluorescent protein; EDEV: endothelial-derived extracellular vesicles; LPS: lipopolysaccharide; p18wt: wild-type p18; ns siRNA: non-
specific control siRNA; Rab4Q67L: dominant active Rab4; Rab4S22N: dominant negative Rab4.
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from these cells did not display increased GFP fluorescence
compared to the untransfected control (Table 1a). To exam-
ine whether p18wt overexpression impacted specific features
of EDEVs in the presence or absence of LPS, the extracel-
lular vesicle concentration (Table 1b) and protein concen-
tration of the vesicles were measured as a ratio of the total
number of endothelial cells (Table 1c). LPS significantly
increased the concentration of EDEVs and protein concen-
tration in EDEVs from cells overexpressing GFP and
p18N39 but had no effect on these parameters in
EDEVs isolated from endothelial cells overexpressing
p18wt (Table 1b and c). This corresponds to a significant
increase in permeability observed following treatment of
naı¨ve LMVEC with EDEVs isolated from cells treated
with LPS (vehicle: 100 8.3% versus LPS: 151.4 6.9%).
Taken together, these data suggest that, in settings of
ARDS, barrier-disruptive, protein-rich EDEVs are released.
The data also show that p18wt-overexpressing cells produce
low-protein EDEVs, which protect the pulmonary endothe-
lium from LPS-induced vascular leak.
Extracellular vesicles derived from endothelial cells
overexpressing dominant active or non-endosome binding
Rab4 exert no effect on LPS-induced barrier permeability
To assess whether this protective role of p18 is linked to its
role in recycling cargo to the cell surface, the effect of the
pro-recycling Rab4 GTPase was studied using the constitu-
tively active Rab4Q67L and dominant negative Rab4S22N
mutants. Previous studies have demonstrated a role for
dominant active Rab4 in protection of the pulmonary endo-
thelium whilst the non-endosomal binding Rab4 disrupts
Table 1. Characterization of endothelial cells and the extracellular vesicles isolated from endothelial cells overexpressing p18 and Rab4
constructs.
a)
Sample
Level of fluorescence (O.D.485/530 nm)
Transfected cDNA
UT GFP p18wt p18N39 Rab4Q67L Rab4S22N
Endothelial cells 20 5 1127 134 1184 139 1177 94 1537 128 1304 89
EDEV 16 4 19 2 14 1 16 2 16 3 19 4
b)
Treatment
EDEV concentration (108 vesicles/ml)
Transfected cDNA
UT GFP p18wt p18N39 Rab4Q67L Rab4S22N
Vehicle 0.18 0.03 0.17 0.02 0.17 0.01 0.18 0.02 0.18 0.02 0.18 0.02
LPS 1.16 0.11* 1.16 0.10* 0.25 0.03 1.16 0.09* 1.12 0.10* 1.04 0.05*
c)
Treatment
EDEV protein concentration/endothelial cell number
Transfected cDNA
UT GFP p18wt p18N39 Rab4Q67L Rab4S22N
Vehicle N.D 0.10 0.016 0.10 0.016 0.14 0.022 0.15 0.032 0.17 0.031
LPS N.D. 0.33 0.020* 0.12 0.012 0.33 0.093* 0.31 0.039* 0.31 0.036*
Notes: LMVECs were transiently transfected with p18wt, p18N39, Rab4Q67L, Rab4S22N, or GFP cDNA. Following 48 h, EDEV were isolated from the media. Table a:
The level of GFP fluorescence of both endothelial cells (1 106) and isolated EDEV (20mg) was measured at 488 nm. Background fluorescence, using DPBS, was
quantified as 15 7 O.D. In a separate experiment, following 48 h from transient transfection, LMVECs were treated with LPS (1 mg/ml) for a further 6 h. Endothelial
cell number was determined and EDEV were isolated from the media. Table b: The concentration of EDEV was quantified using the qNano Gold, normalized to
media as a control, and is presented as 108 vesicles/ml. EDEV in media (no cells present) were quantified as below accurate detection (<0.00001 108 vesicles/ml).
Table c: Protein concentration of EDEV (mg/ml) is shown as a ratio of endothelial cell number (106). Data are presented as mean SEM. n¼ 6.
*p< 0.05 vs vehicle.
UT: un-transfected control; N.D.: not done; EDEV: endothelial-derived extracellular vesicles; GFP: green fluorescent protein; p18wt: wild-type p18; p18N39: non-
endosomal binding p18 mutant; Rab4Q67L: dominant active Rab4; Rab4S22N: dominant negative Rab4.
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the endothelial monolayer.18 In the present study, EDEVs
from both Rab4Q67L- and Rab4S22N-overexpressing
LMVEC exerted no effect on naı¨ve LMVEC monolayers,
either in the presence or absence of LPS, similar to
EDEVs from GFP-overexpressing cells (Fig. 1e–h). As for
EDEVs from p18wt-overexpressing endothelial cells, GFP
fluorescence was observed at low levels in the vesicles
(Table 1a). Interestingly, extracellular vesicle concentration
(Table 1b) and protein concentration in EDEVs (Table 1c)
from Rab4Q67L- or Rab4S22N-overexpressing cells was sig-
nificantly higher when LMVECs were exposed to LPS, simi-
lar to EDEVs from GFP-overexpressing cells. These studies
thus demonstrate that the effect of p18 on pathogenicity of
extracellular vesicles is independent of Rab4-positive endo-
somal recycling.
Extracellular vesicles derived from endothelial cells
over expressing p18wt display an altered miRNA profile
which mediates barrier protective effects
We next sought to understand the potential mechanism
through which EDEVs isolated from LMVEC overexpres-
sing p18wt could protect the pulmonary endothelium.
A range of studies have demonstrated the key role of
miRNAs in regulating endothelial barrier function27–29
and the potential for EDEVs to act as carriers for these
miRNA.9 Our next experiments therefore studied the profile
of miRNA present within EDEVs isolated from cells over-
expressing p18wt or GFP control. In untreated cells, the
expression profile for miRNA in EDEVs was considerably
altered in cells overexpressing p18wt compared to GFP con-
trol (Table 2a). Following exposure to LPS, there were also
differences in miRNA expression in EDEVs isolated from
cells overexpressing p18wt compared to GFP (Table 2b,
Fig. 2b). Interestingly, LPS exposure causes upregulation
of 9 miRNAs and downregulation of 21 miRNAs in
EDEVs isolated from GFP-overexpressing cells (Table 2b).
In contrast, in EDEVs isolated from cells overexpressing
p18wt, there were 10 miRNAs upregulated and 33 miRNAs
downregulated following LPS exposure (Table 2b). Of note,
EDEVs isolated from p18wt-overexpressing cells, both treated
and untreated with LPS, displayed upregulation of seven
miRNAs which were unique to this construct (miR-30a-5p,
let-7i-5p, miR-103-3p, miR-96-5p, miR-196a-5p, miR-324-5p,
and miR-137-3p) (Table 2a (i) and b (i)). To establish whether
these miRNA play a role in the barrier-protective effect of
these EDEVs, LMVECs were transfected with miRNA
mimics and endothelial permeability was assessed using the
monolayer flux assay. To demonstrate transfection efficiency
with these mimics, cel-miR67-Dy547 control was used and a
significant increase in fluorescence was observed from
1351 105 mean fluorescence units (MFU) compared to
369 78 MFU in the scrambled, non-specific miRNA
mimic control. There was, however, no significant effect of
transfection of cel-miR67-Dy547 on cell viability, measured
by CCK8 assay (data not shown). At baseline conditions,
transfection with all miRNA mimics had no significant
effect on endothelial monolayer basal permeability (Fig. 2c).
Following exposure to miR-103-3p, miR-196a-5p, and miR-
324-50 mimics, there was no significant change in LPS-
induced endothelial monolayer permeability (Fig. 2c).
Interestingly, transfection with mimics for miR-30a-5p,
miR-96-5p, and miR-137-5p significantly reduced permeabil-
ity induced by LPS whilst only let-7i-5p miRNA mimic was
able to completely block LPS-mediated leak (Fig. 2c). These
data indicate that p18wt regulates the miRNA cargo of
EDEVs and that these cargo include barrier-protective
miRNAs in in vitro settings of ARDS.
p18 expression is downregulated in lungs and pulmonary
vasculature in settings of ARDS
Given the protective role of p18 in the pulmonary vascula-
ture, and the link between ARDS and pathogenic EDEVs,8
our next experiments studied whether p18 expression in the
pulmonary vasculature is affected in settings of ARDS. The
P. aeruginosa in vivo model of pulmonary edema was used
which we have previously demonstrated causes a significant
41.5% increase in wet-to-dry lung weight ratio.17,18 In the
present study, we observed a significant decrease in p18
expression in lung homogenates from P. aeruginosa-infected
mice, compared to saline controls (Fig. 3a). Similarly, using
an in vitro model of injury, LMVECs exposed to LPS, we
observed a significant decrease in p18 expression (Fig. 3b).
These data demonstrate that the endosomal protein, p18, is
downregulated in the pulmonary microvasculature in
in vitro and in vivo settings of ARDS.
Discussion
In the present study, we demonstrate, for the first time, that
p18wt-overexpressing pulmonary endothelial cells release
barrier-protective EDEVs. Using an established technique
to isolate EDEVs, our findings show that the protein-rich
EDEVs, which are shed when the endothelium is exposed to
LPS, increased barrier permeability. In contrast, EDEVs
from LPS-challenged cells overexpressing p18wt do not dis-
play this effect on endothelial barrier integrity. We further
demonstrate that this protective effect of p18 is through the
ability to bind to the endosome. Findings from endothelial
cells overexpressing Rab4 active and inactive mutants dem-
onstrate that the early endosome regulator does not affect
EDEVs. Our studies indicate the miRNA cargo within
EDEVs released from p18wt-overexpressing cells, which
may influence permeability of the endothelial monolayer.
Finally, we demonstrate a decrease in pulmonary p18 pro-
tein expression in both in vitro and in vivo models of
ARDS. Taken together, our findings indicate the import-
ance of p18 in regulating pulmonary endothelial barrier
function through the release of barrier-protective EDEVs.
Studies have demonstrated that, in settings of ARDS, the
endothelium releases pathogenic EDEVs which can result in
6 | p18 microparticle paper Harrington et al.
Table 2. miRNA expression in EDEVs isolated from endothelial cells overexpressing p18wt in the presence and absence of LPS.
a) i)
Upregulated miRNA in p18wt-overexpressing cells exposed to vehicle (relative to GFP-overexpressing cells exposed to vehicle)
miRNA Fold upregulation Adjusted p value miRNA Fold upregulation Adjusted p value
miR-142-5p 0.395 0.04126 miR-19a-3p 0.864 0.46892
miR-16-5p 0.180 0.00721 miR-106b-5p 6.770 0.00281
let-7b-5p 4.479 0.03786 miR-101a-3p 0.162 0.03392
let-7f-5p 0.180 0.06390 miR-425-5p 0.982 0.00740
miR-30e-5p 0.172 0.00297 miR-15b-5p 0.412 0.00426
miR-181a-5p 0.876 0.14804 miR-28-5p 0.027 0.24177
miR-29a-3p 0.018 0.00164 miR-18a-5p 1.328 0.00195
miR-144-3p 0.001 0.24574 let-7i-5p 0.253 0.00313
miR-30d-5p 6.817 0.00915 miR-222-3p 0.757 0.00284
miR-19b-3p 0.122 0.16661 miR-23b-3p 2.512 0.03225
miR-22-3p 0.225 0.00256 miR-186-5p 0.701 0.00491
miR-122-5p 0.027 0.06574 miR-7a-5p 2.084 0.00952
miR-150-5p 0.021 0.05910 miR-30c-5p 0.219 0.00140
miR-32-5p 2.671 0.02835 miR-125a-5p 0.121 0.00117
miR-140-5p 0.470 0.04396 miR-151-5p 0.458 0.00941
miR-141-3p 0.054 0.00241 miR-196b-5p 0.453 0.36637
miR-92a-3p 0.072 0.39677 miR-140-3p 0.102 0.00278
miR-322-5p 3.694 0.01813 miR-100-5p 0.029 0.79671
miR-191a-5p 0.712 0.14738 miR-103-3p 0.473 0.00567
miR-17-5p 5.348 0.01930 miR-96-5p 0.344 0.02990
miR-9a-5p 0.127 0.00132 miR-320-3p 1.239 0.00421
miR-26a-5p 0.330 0.24840 let-7a-5p 0.228 0.00327
miR-20a-5p 9.817 0.02835 miR-126a-3p 0.088 0.26361
miR-27b-3p 0.023 0.07468 miR-342-3p 7.009 0.03275
miR-26b-5p 0.312 0.00384 miR-375-3p 0.043 0.04912
miR-146a-5p 0.483 0.06670 miR-196a-5p 0.837 0.00323
miR-200c-3p 1.624 0.36359 miR-324-5p 0.664 0.04302
miR-30a-5p 7.712 0.01102 miR-137-3p 8.981 0.00166
a) ii)
Downregulated miRNA in p18wt-overexpressing cells exposed to vehicle (relative to GFP-overexpressing cells exposed to vehicle)
miRNA Fold downregulation Adjusted p value miRNA Fold downregulation Adjusted p value
miR-142-3p –3.110 0.04152 let-7c-5p –0.141 0.00757
miR-21-5p –0.501 0.05038 miR-423-3p –0.150 0.00155
miR-29b-3p –1.040 0.04332 miR-376c-3p –1.306 0.00109
miR-143-3p –9.260 0.01100 miR-195-5p –0.058 0.08020
miR-24-3p –0.085 0.05068 miR-25-3p –0.014 0.00187
miR-27a-3p –0.007 0.06264 miR-29c-3p –0.131 0.00758
miR-124-3p –0.181 0.00705 let-7d-5p –0.306 0.00460
miR-128-3p –0.204 0.00818 miR-181b-5p –0.900 0.01916
miR-185-5p –0.030 0.00210 miR-223-3p –13.977 0.02146
miR-210-3p –0.018 0.00387 miR-194-5p –0.136 0.00715
miR-23a-3p –0.065 0.05075 miR-374-5p –0.706 0.00146
(continued)
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Table 2. Continued
a) ii)
Downregulated miRNA in p18wt-overexpressing cells exposed to vehicle (relative to GFP-overexpressing cells exposed to vehicle)
miRNA Fold downregulation Adjusted p value miRNA Fold downregulation Adjusted p value
miR-99a-5p –0.050 0.09077 let-7e-5p –0.293 0.00122
miR-130a-3p –0.101 0.03982 miR-182 –1.512 0.03445
miR-93-5p –1.227 0.04400 miR-378a-3p –4.817 0.02405
b) i)
Upregulated miRNA in cells exposed to LPS (relative to cells exposed to vehicle)
cDNA transfected GFP Fold upregulation Adjusted p value p18wt Fold upregulation Adjusted p value
Common miRNA miR-142-3p 0.531 0.04854 miR-142-3p 0.730 0.04542
miR-29b-3p 0.157 0.04671 miR-29b-3p 0.092 0.01197
miR-24-3p 1.028 0.02386 miR-24-3p 0.970 0.01939
Differences in miRNA miR-124-3p 0.885 0.02851 miR-30a-5p 2.648 0.09452
miR-29c-3p 0.539 0.04350 let-7i-5p 1.315 0.01741
miR-223-3p 1.915 0.00706 miR-103-3p 1.701 0.04301
let-7e-5p 1.443 0.04229 miR-96-5p 0.359 0.06161
miR-182 1.798 0.02560 miR-196a-5p 1.124 0.00217
miR-143-3p 1.382 0.05025 miR-324-5p 1.262 0.00982
miR-137-3p 1.374 0.01883
b) ii)
Downregulated miRNA in cells exposed to LPS (relative to cells exposed to vehicle)
cDNA transfected GFP Fold downregulation Adjusted p value p18wt Fold downregulation Adjusted p value
Common miRNA miR-142-5p –0.835 0.04831 miR-142-5p –0.731 0.01006
miR-16-5p –1.675 0.0256 miR-16-5p –1.319 0.01809
miR-126a-3p –0.909 0.01733 miR-126a-3p –1.195 0.01229
miR-181a-5p –2.301 0.01961 miR-181a-5p –1.791 0.0416
miR-144-3p –0.774 0.21246 miR-144-3p –0.633 0.03298
miR-150-5p –0.836 0.03441 miR-150-5p –1.031 0.08415
miR-92a-3p –0.145 0.09247 miR-92a-3p –0.293 0.05467
miR-322-5p –0.631 0.02535 miR-322-5p –0.515 0.07646
miR-191a-5p –1.437 0.01125 miR-191a-5p –1.328 0.02054
miR-146a-5p –2.160 0.00921 miR-146a-5p –2.016 0.01633
miR-200c-3p –1.905 0.01545 miR-200c-3p –2.392 0.02501
miR-99a-5p –0.366 0.01849 miR-99a-5p –0.527 0.04049
miR-19a-3p –2.050 0.00273 miR-19a-3p –3.109 0.03433
miR-28-5p –1.138 0.08351 miR-28-5p –1.583 0.04108
miR-23b-3p –0.479 0.02628 miR-23b-3p –0.927 0.06066
miR-186-5p –2.027 0.03024 miR-186-5p –2.210 0.01858
miR-7a-5p –1.729 0.00747 miR-7a-5p –1.850 0.01917
miR-320-3p –0.668 0.01615 miR-320-3p –0.886 0.0672
miR-196b-5p –0.395 0.00883 miR-196b-5p –0.135 0.01665
miR-196a-5p –0.006 0.00867 miR-196a-5p –0.017 0.03588
Differences in miRNA miR-19b-3p –0.339 0.01249 miR-21-5p –1.281 0.02489
miR-100-5p –0.244 0.04831 let-7b-5p –3.022 0.04926
(continued)
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increased vascular disruption and inflammation.8,14 In these
studies, EDEVs were isolated from the endothelium in both
in vitro and in vivo experiments. Using human pulmonary
arterial endothelial cells, previous studies have isolated
EDEVs with the centrifugation method and demonstrated
that 95% of EDEVs collected were <1mM and double posi-
tive for annexin V and CD31.8 Using this same protocol, we
isolated EDEVs from rat LMVECs and, similar to Letsiou
et al., we observed an increase in EDEV concentration fol-
lowing LPS exposure.8 We further demonstrate that EDEVs
from LPS-treated cells increased permeability of a naı¨ve
monolayer. Given the nature of the centrifugation steps, it
is unlikely that remnants of the endotoxin would remain in
the EDEV sample. Furthermore, endothelial injury, such as
cyclic stretch, has also been shown to increase the shedding of
pathogenic EDEVs from the pulmonary endothelium. Our
findings therefore confirm that LPS, an in vitro model of
ARDS, promotes the release of barrier-disruptive EDEVs,
resulting in an increase in leak across the monolayer.
In ARDS, pathogenic EDEVs have been demonstrated to
contain potentially barrier-disruptive cargo such as
moesin.8,12 We have previously shown that p18 overexpres-
sion tightens the endothelial barrier17 and demonstrate that
levels of p18 protein were not elevated in EDEVs from cells
overexpressing the protein. These findings indicate that the
specific cargo within EDEVs from p18-overexpressing cells
is key to the protective effect. Extracellular vesicles can be
comprised of an array of biological materials, such as
miRNA, lipids, and surface proteins.9,30,31 Indeed in the
present study, we demonstrate that p18 overexpression in
cells alters the miRNA expression profile of EDEVs in an
in vitro model of healthy and ARDS conditions, and spe-
cifically upregulates the expression of barrier-protective
miRNA (miR-30a-5p, miR-96-5p, miR-137-5p, let-7i-5p)
in EDEVs. Whilst these miRNA have not been previously
associated with vascular leak, miR-137-5p and miR-30a-5p
are both linked to pro-angiogenic processed whilst miR-96-
5p has been shown to be downregulated in settings of oxi-
dative stress in ARPE-19 cells.32–34 Interestingly, in the
kidney and brain, let-7i-5p has been closely linked with
anti-inflammatory processes in vitro and in vivo with ele-
vated miRNA linked to decreased TLR4 expression and
signaling.35,36 Thus it is possible that EDEVs rich in let-7i-
5p miRNA protect the pulmonary endothelium by reducing
TLR4 expression, and thus reducing the ability of LPS to
cause barrier disruption. These studies indicate a potential
mechanism through which p18 regulates miRNA cargo of
EDEV to exert the barrier-protective effects observed.
Further studies are needed, however, to assess whether
these miRNAs are responsible for the protective effect
exerted by EDEVs isolated from p18-overexpressing cells.
miRNAs are processed through multiple cellular steps;
pre-miRNA is synthesized in the nucleus and exported, via
exportin 5, into the cytoplasm for cleavage by Dicer and
AGO proteins into functional miRNA.16 The TAR-RNA
binding protein (TRBP) binds Dicer to stabilize the pre-
miRNA:Dicer complex and it has been demonstrated that
TRBP is regulated by mitogen activated kinase (MAPK)-
Table 2. Continued
b) ii)
Downregulated miRNA in cells exposed to LPS (relative to cells exposed to vehicle)
cDNA transfected GFP Fold downregulation Adjusted p value p18wt Fold downregulation Adjusted p value
miR-106b-5p –1.583 0.02775
miR-18a-5p –1.549 0.03768
miR-181b-5p –0.505 0.02321
miR-223-3p –0.192 0.01652
miR-374-5p –0.672 0.01767
miR-423-3p –0.925 0.04923
miR-376c-3p –0.382 0.06346
miR-195-5p –1.533 0.01962
miR-222-3p –0.672 0.07756
miR-128-3p –0.880 0.05555
miR-185-5p –1.292 0.01253
miR-378a-3p –1.143 0.01006
Notes: LMVECs were transiently transfected with p18wt or GFP cDNA. Following 48 h from transient transfection, LMVECs were treated with vehicle (a) or LPS
(1 mg/ml) (b) for a further 6 h. EDEV were isolated from the media, miRNA content was assessed using the miScript system and expressed as upregulated (i) or
downregulated (ii) when compared to either GFP (a) or vehicle control (vehicle for LPS) (b). In panel (b), ‘‘common miRNAs’’ refers to those found in EDEVs
isolated from both GFP- and p18wt-overexpressing cells treated with LPS. ‘‘Differences in miRNA’’ refers to miRNA which were found only in either GFP-
overexpressing cells treated with LPS or p18wt-overexpressing cells treated with LPS. n¼ 4, expression data expressed as fold upregulation or downregulation,
adjusted p value using the Benjamini–Hochberg correction. miRNA and p values in bold denotes a statistically-significant (adjusted p< 0.05) relative to GFP-
overexpressing cells (panel a) or vehicle-treated cells (panel b).
p18wt: wild-type p18; GFP; green fluorescent protein; LPS: lipopolysaccharide.
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extracellular signal-regulated kinase (ERK) phosphoryl-
ation.37 Although there have been no studies linking p18
with miRNA processing, we have previously shown that
p18 activates p38-MAPK in pulmonary endothelial cells.17
It is therefore possible that p18 regulates miRNA process-
ing, and thus the composition of miRNAs expressed in
EDEVs, through a MAPK-dependent pathway. Further
studies are therefore needed to establish the mechanism
through which p18 regulates miRNA cargo in EDEVs,
with the aim of identifying novel therapeutic targets to
reduce endothelial permeability in settings of ARDS.
The endosome adaptor protein, p18, has been identified
at the early and late endosome to regulate mTOR and MEK
activity17,20,21; however, despite these studies, there is still
limited data regarding the role of p18 in the lung. In con-
trast, Rab GTPases are a well-established family of endo-
some regulator proteins which are known to orchestrate the
trafficking of endosomes through the cell. We have
previously demonstrated the protective role of the endoso-
mal proteins, Rab4 GTPase and p18, on endothelial barrier
function.17,18 The protective effects of both proteins is
mediated by the ability of Rab4 and p18 to bind to the
endosome; the non-endosome binding mutants Rab4S22N
and p18N39, respectively, had no effect on endothelial per-
meability. However, there are two different mechanisms
through which the proteins mediate endothelial barrier pro-
tection. Rab4 attenuated LPS-induced leak through sup-
pressed ERK activity,18 whereas p18 enhanced trafficking
of VE-cadherin to the adherens junction to attenuate LPS-
induced permeability.17 In contrast, in the present study,
EDEVs from cells overexpressing p18, but not the early
endosome protein Rab4, protected the endothelium against
LPS-induced permeability. These data indicate that p18-
mediated release of protective EDEVs is independent of its
role in trafficking the early endosome. Interestingly, p18wt-
overexpressing endothelial cells demonstrated improved
Fig. 2. p18 overexpression regulates the release of barrier-protective miRNA in extracellular vesicles released from PAEC. Equivalent numbers
of LMVECs were transiently transfected with p18wt or GFP cDNA as a vector control (panel b) or transfected with miRNA mimics and a
scrambled, non-specific (ns) control (panel c). Following 42 h, cells were exposed to LPS, or saline control, for a further 6 h. Panel b: EDEV were
then collected for RNA extraction and miScript array analysis (panel a). Heat maps demonstrating the change in miRNA profile were analyzed
using Qiagen GeneGlobe Data Analysis center. miRNA expression profile in EDEVs from cells overexpressing GFP (panel b(i)) or p18wt (panel b(ii))
following exposure to LPS. Panel c: % permeability of the endothelial monolayer measured by FITC monolayer flux assay. Data are presented as
mean SEM. n¼ 5–6. *p< 0.05 vs vehicle for LPS, #p< 0.05 vs ns miRNA treated with LPS.
GFP: green fluorescent protein; EDEV: endothelial-derived extracellular vesicles; p18wt: wild-type p18; LPS: lipopolysaccharide.
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barrier function at baseline conditions,17 whilst the present
studies demonstrate that EDEVs from p18wt-overexpressing
cells exert no such protective effect at baseline conditions.
Therefore, it is likely that p18 regulates the pulmonary
endothelium through a range of different mechanisms to
reduce barrier leak.
Whilst these findings indicate the importance of EDEVs
on endothelial barrier function, there are several other cell
types within the pulmonary system which release extracellular
vesicles and have been shown to play a role in vascular func-
tion. For example, increased platelet-derived extracellular
vesicles have been observed following LPS exposure to
increased endothelial cell activation and disruption,38 whilst
LPS-stimulated macrophage extracellular vesicles increase
fluid and protein leak into the alveoli.39 Given the expression
of p18 in both platelets and macrophages40,41 and the
decrease in p18 expression in lungs from an ARDS
model, further studies should be considered to assess whether
this endosomal protein could also promote the release of pro-
tective extracellular vesicles from other cell types in the lungs.
Highlights
. The endosomal protein, p18, promotes the release of pro-
tective extracellular vesicles which reduce LPS-induced
leak across the pulmonary endothelial barrier.
. Extracellular vesicles released from pulmonary endothe-
lial cells overexpressing p18wt display markedly different
miRNA expression profile, relative to GFP-overexpres-
sing endothelial cells.
. p18 protein expression is downregulated in the pulmon-
ary endothelium and lungs of in vitro and in vivo models
of ARDS respectively.
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Fig. 3. p18 expression is downregulated in settings of ARDS. (a) Lung homogenates (100 mg) from mice exposed to Pseudomonas aeruginosa
(PA103), or PBS vehicle, for four hours were assessed by Western blotting for the expression of p18. (b) Lysates from lung microvascular
endothelial cells (50 mg) exposed to LPS, or saline control, for six hours. Densitometry was performed to show protein expression, as a ratio
compared to load control (actin) and normalized to vehicle control. Representative immunoblots are shown. Data are presented as mean SEM
n¼ 5. *p< 0.05 vs vehicle.
LPS: lipopolysaccharide.
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